Dasatinib Dosing for Aging: Intermittent vs Continuous Protocols
Expert Summary
The dasatinib senolytic protocol uses the same 100 mg dose as CML treatment but dramatically reduces total exposure by limiting treatment to 2–3 days per quarter (vs 365 days/year for CML). This intermittent approach maintains sufficient plasma drug levels to trigger senolytic apoptosis during the burst window while avoiding the chronic exposure that drives pleural effusion and peripheral neuropathy.
Key Facts
- Standard senolytic protocol: Dasatinib 100 mg + quercetin 1,000 mg, days 1 and 2 of a quarterly cycle. This is the most clinically studied protocol from Mayo Clinic and University of Texas trials.
- Extended burst protocol: Days 1, 3, 5 of a 3-week cycle (as used in the original IPF pilot). The skipped days reduce cumulative exposure while maintaining repeat senolytic windows.
- Pharmacokinetic rationale: Dasatinib has a half-life of 3–5 hours. Peak plasma levels are maintained for 12–24 hours after dosing. A 2-day protocol provides two consecutive senolytic exposure windows.
- Dosage flexibility: Some longevity physicians use 50 mg (half dose) for initial testing, particularly in older or frail patients. 50 mg retains senolytic activity (the BCL-2/kinase inhibition IC50 is well within 50 mg plasma levels) while reducing side effect risk.
- Frequency adjustment: Quarterly is the most common frequency. Monthly is used in more aggressive protocols (for individuals with high inflammatory burden or advanced age). Annual is insufficient based on senescent cell reaccumulation data.
- No dose titration: Unlike with many drugs, dasatinib for senolysis does not require dose escalation. The 100 mg dose from the established protocol is used from the first cycle.
Recommended Products
Frequently Asked Questions
What happens if I take dasatinib more frequently than quarterly?
More frequent dosing increases total cumulative exposure and side effect risk without clear additional senolytic benefit. Monthly D+Q is used in some protocols for older individuals with high disease burden, but requires closer physician monitoring.
Should I take dasatinib in the morning or evening?
No clinical evidence favors a specific timing. Taking with food reduces GI side effects. Morning dosing may align with cortisol peaks that influence cellular stress responses, but this is speculative. Consistency in timing across the protocol days is more important than specific time of day.
Is there a minimum age for D+Q protocol?
Clinically, D+Q is appropriate for adults with significant age-related disease or functional decline. For healthy individuals, most longevity physicians suggest natural senolytics (fisetin, quercetin) first, considering D+Q from age 60–65 or earlier if warranted by biomarkers.
Scientific References
- Xu M et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018. PMID: 29988130
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine. 2019. PMID: 30616998